Review of: "Personalized (tailored) treatment with antiresorptive drugs (bisphosphonates, denosumab) in patients with bone metastases from solid tumors – A “Pico” document by Rete Oncologica Piemonte-Valle D’Aosta Bone Metastatic Disease Study Group"

Stefano Sganga

1 Policlinco Tor Vergata

Potential competing interests: No potential competing interests to declare.

Thank you for the opportunity of reviewing this paper, it is a very interesting study. This study performs an analysis to understand which drug is most appropriate in patients with multiple bone metastases. As the article points out, since there are no studies to directly compare different antiresorptive agents. Therefore, the authors of the study conducted an analysis based on drug costs, logistics and facilities, patients' preferences, renal toxicity, and expected risk of Medication-Related Osteonecrosis of the Jaw (MRONJ) and the timing of administration in order to define a personalized treatment for each patient.